Effect of semaglutide on elderly diabetic nephropathy and its effect on NLRP3 inflammasome pathway
Objective To investigate the efficacy of semaglutide in the treatment of elderly diabetic nephropathy (DN) and its effect on the NLRP3 inflammasome pathway.Methods A total of 80 elderly patients with DN who were treated at the First People's Hospital of Huoqiu County,Lu'an from January 2022 to January 2024 were divided into a control group and an observation group,each with 40 cases according to the random number table method.Patients in the control group received the routine treatment for clinical DN,while those in the observation group received combined treatment with semaglutide based on the treatment regimen of the control group.The treatment duration for patients in both groups was 3 months.After 3 months of treatment,blood glucose levels,renal function indices,NLRP3 inflammatory body pathway molecule expression in peripheral blood mononuclear cells(PBMCs) and NLRP3 inflammatory body downstream factor content in serum were compared between the two groups.Additionally,differences in the occurrence of drug-related adverse reactions during treatment were also assessed.Results After 3 months of treatment,there were no significant differences in fasting blood glucose(FBG) and glycosylated hemoglobin (HbA1c) levels between the two groups (t=0.698,0.894,P>0.05).The levels of blood creatinine (Scr),urea nitrogen (BUN),and urinary creatinine ratio (ACR),the mRNA expressions of NLRP3 and caspase-1 in PBMCs,and the contents of serum interleukin-1β (IL-1β),interleukin-18 (IL-18) and gasdermin D-N terminal (GSDMD-N) in the observation group were lower than those in the control group,and the differences were statistically significant (t=7.884,4.049,2.216,3.677,5.355,7.336,6.654,7.835,P<0.05).During the 3 months of treatment,there was no significant difference in the incidence of drug-related adverse reactions between the two groups (x2=0.581,P>0.05).Conclusion The treatment of semaglutide in elderly patients with DN is helpful in improving efficacy and ensuring treatment safety.The mechanism of its action may be related to the inhibition of the NLRP3 inflammasome pathway.
万方数据
维普
